4-hydroxycyclohexadieneone (10) against renal, colon cancer cell lines, while the antitumor benzothiazole prodrug, Phortress (11) , is currently under pharmacological investigation in a phase I clinical trial in the UK. Yoshida et al. (12) synthesized a highly potent benzothiazole derivative bearing amido residue, 2,6-dichloro-N-(2-(cyclopropanecarboxamido)benzo[d]thiazol-6-yl)benzamide (Scheme 1) with excellent in vivo inhibitory effect on tumor growth.
On the other hand, thiazoles have also attracted great interest as anti tumour agents (13) . Since varying substituents is a common method for drug design in medicinal chemistry and a useful medical value of substituted benzothiazols, such as aryl or amido groups at C-2 (Scheme 1), we aimed to synthesize new benzothiazole derivatives bearing amido-mercapto substituted 1,3,4-oxadiazoles and to investigate their antitumor and antiviral activities.
EXPERIMENTAL
Melting points were determined on melting point apparatus (Sanyo Gallenkamp, UK) and are uncorrected. IR spectra were recorded on an FTX 3000 MX BioRad Excalibar Series IR spectrophotometer, Bio Rad Laboratories (USA) using KBr pellets. 1 H NMR spectra were recorded on a Bruker 300 MHz spectrometer (Germany). Mass spectra were recorded on a MAT-112-S spectrometer at 70 eV and GCMS 5973 Inert mass selective detector, Agilent Technologies (USA); elemental analyses were performed on a CHNS-932 elemental analyzer, Leco Corporation (USA).
Analytical data for the synthesized compounds are given in Tables I and II . Synthetic routes are presented in Scheme 2.
Syntheses General procedure for the synthesis of 4-alkyl-, 4-halo-, 3,4-dichlorophenoxyalkanoic acids (1a-h
). -These compounds were prepared previously in our laboratory (14) by the treatment of 2-bromopropanoic acid or 2-bromobutanoic acid with commercial substituted phenols in aqueous NaOH. 2-(Bromophenoxy)propanoic acid (1a), 2-(bromophenoxy)butanoic acid (1b), 2-(chlorophenoxy)propanoic acid (1c), 2-(chlorophenoxy)butanoic acid (1d), 2-(3,4-dichlorophenoxy)propanoic acid (1e), 2-(3,4-dichlorophenoxy)butanoic acid (1f), 2-(p-tolyloxy)propanoic acid (1g), 2-(p-tolyloxy)butanoic acid (1h) were prepared by condensation of p-bromophenol with 2-bromopropanoic acid, p-bromophenol with 2-bromobutanoic acid, 
General procedure for the synthesis of 4-alkyl-, 4-halo-, 3,4-dichlorophenoxyalkanoic methyl esters (2a-h
). -2-(4-Bromophenoxy)propanoic methyl ester (2a), 2-(4-bromophenoxy)butanoic methyl ester (2b), 2-(4-chlorophenoxy)propanoic methyl ester (2c), 2-(4-chlorophenoxy)butanoic methyl ester (2d), 2-(3,4-dichlorophenoxy)propanoic methyl ester (2e), 2--(3,4-dichlorophenoxy)butanoic methyl ester (2f), 2-(p-tolyloxy)propanoic methyl ester (2g), 2-(p-tolyloxy)butanoic methyl ester (2h) were prepared according to the Fischer esterfication procedure (15) , by treatment of 1a-h with acidic MeOH. Compounds 2a-h were used for the next step without further purification.
General procedure for the synthesis of 4-alkyl-, 4-halo-, 3,4-dichlorophenoxyalkanoic acid hydrazides (3a-h
). -To a solution of 2 (3.80 mmol) in EtOH (20 mL), hydrazine hydrate (5.0 mL) was added and the solution was heated under reflux for 3-4 h. After cooling, the solution was evaporated to dryness and the residue was recrystallized from EtOH or EtOH/MeOH. 4-Bromophenoxypropionic acid hydrazide (3a), 4-bromophenoxybutyric acid hydrazide (3b), 4-chlorophenoxypropionic acid hydrazide (3c), 4-chlorophenoxybutyric acid hydrazide (3d), 3,4-dichlorophenoxypropionic acid hydrazide (3e), 3,4-dichlorophenoxybutyric acid hydrazide (3f), 4-methylphenoxypropionic acid hydrazide (3g) and 4-methylphenoxybutyric acid hydrazide (3h) were prepared from 2a (0.98 g), 2b (1.04 g), 2c (0.81 g), 2d (0.87 g), 2e (0.95 g), 2f (1.0 g), 2g (0.74 g), and 2h (0.79 g), respectively.
General procedure for the synthesis of 1,3,4-oxadiazole-2-thiones (5a-h
). -Hydrazide 3 (10.30 mmol) was added to a stirred solution of KOH (12.37 mmol) in MeOH (30 mL), followed by addition of CS 2 (0.75 mL, 12.37 mmol) dropwise under stirring. The obtained yellow solution was heated under reflux till the evolution of H 2 S ceased (18-20 h). After cooling, the solution was filtered, and the filtrate was poured into ice-cooled water and acidified with 6 mol L -1 HCl to pH 3-4. The precipitated solid was filtered, dried and recrystallized from aq. EtOH to afford pure oxadiazoles. -methylphenoxy) propyl]-1,3,4-oxadiazole-2-thione (5h) were prepared from 3a (2.67 g), 3b (2.81 g), 3c (2.21 g), 3d (2.36 g), 3e (2.56 g), 3f (2.71 g), 3g (2.00 g), and 3h (2.14 g), respectively.
General procedure for the synthesis of N-(benzothiazol-2-yl)-2-(5-(1-(4-or 3,4-halo-or alkylphenoxy)ethyl)-1,3,4-oxadiazole-2-yl-thio)acetamides (6a-h
). -To a solution of 5 (0.95 mmol) in acetone (40 mL), benzothiazolyl chloroacetamide (4) (1.05 mmol) and anhydrous K 2 CO 3 (3.81 mmol) were added and the mixture was stirred at 23°C for 5 h. The resulting reddish solution was heated under reflux till completion of the reaction. After cooling, the reaction mixture was filtered and the filtrate was concentrated to 10 mL, followed by addition of cold water. The resulting solid was filtered, dissolved in acetone and boiled with decolorizing charcoal. The charcoal was filtered and the filtrate was evaporated to dryness to afford pure benzothiazole derivatives 6a-h. N-(benzothiazol-2-yl)-2-{5-[1-(4-chlorophenoxy)ethyl]-1,3,4-oxadiazole-2-yl-thio}acetamide (6c), N-(benzothiazol-2-yl)-2-{5-[1-(4-chlorophenoxy)propyl]  -1,3,4-oxadiazole-2-yl-thio}acetamide (6d), N-(benzothiazol-2-yl)-2-{5-[1-(3,4-dichlorophenoxy)ethyl]-1,3,4-oxadiazole-2-yl-thio}acetamide (6e), N-(benzothiazol-2-yl)-2-{5-[1--(3,4-dichlorophenoxy) Table III. Compounds were dissolved in DMSO at 100 mmol L -1 and then diluted in culture medium.
N-(Benzothiazol-2-yl)-2-{5-[1-(4-bromophenoxy)ethyl]-1,3,4-oxadiazole-2-yl-thio}ace-tamide (6a), N-(benzothiazol-2-yl)-2-{5-[1-(4-bromophenoxy)propyl]-1,3,4-oxadiazole-2-
Cytotoxicity assays. -For cytotoxicity tests, run in parallel with antiviral assays, MDBK and BHK cells were resuspended in 96 multiwell plates at an initial density of 61 0 5 and 1´10 6 cells mL -1 , respectively, in maintenance medium, without or with serial dilutions of test compounds. Cell viability was determined after 48-96 h at 37°C in a humidified CO 2 (5%) atmosphere by the 3-tetrazolium bromide method (MTT). Vero 76 cells were resuspended in 24 multiwell plates at an initial density of 4´10 5 cells mL -1 . The cell number of Vero 76 monolayer was determined by staining with the crystal violet dye. For cytotoxicity evaluations, exponentially growing cells derived from human haematological tumors [CD4 + human T-cells containing an integrated HTLV-1 genome (MT-4)] were seeded at an initial density of 1´10 5 cells mL -1 in 96 well plates in RPMI--1640 medium supplemented with 10% faetal calf serum (FCS), 100 units mL -1 penicillin G and 100 mg mL -1 streptomycin. Cell cultures were then incubated at 37°C in a humidi-fied, 5% CO 2 atmosphere in the absence or presence of serial dilutions of the test compounds. Cell viability was determined after 96 h at 37°C by the MTT method.
In vitro antiviral activity. -Compounds 5a-h and 6a-h were tested for their anti--HIV-1 activity in vitro, using IIIB strain in human T-lymphocyte (MT-4) cells, based on a MTT assay. Compounds 5a-h and 6a-h were also evaluated against various viruses: mock--infected MDBK (bovine normal kidney), BVDV (bovine viral diarrhea virus), mock-infected BHK (hamster normal kidney fibroblast), BHK (kidney fibroblast) cells from the YFV (yellow fever virus) and Reo (reovirus 1), mock-infected VERO-76 (monkey normal kidney), HSV-1 (herpesvirus 1), VV (vaccinia virus), VSV (vesicular stomatitis virus), CVB-2 (coxsackievirus B2), Sb-1(poliovirus 1) and RSV (respiratory syncytial virus) by 50% in VERO-76 monolayers. BHK and MDBK cells were seeded in 96-weels plates at a density of 5´10 4 and 31 0 4 cells/well, respectively, and were allowed to form confluent monolayers by incubating overnight in growth medium at 37°C in a humidified CO 2 (5%) atmosphere. Cell monolayers were then infected with 50 mL of a proper virus dilution (in serum-free medium) to give an m.o.i. = 0.01; 1 h later, 50 mL of MEM Earle's medium, supplemented with inactivated foetal calf serum (FCS), 1% final concentration, without or with serial dilutions of test compounds, was added. After 3-4 days incubation at 37°C, cell viability was determined by the MTT method.
Activity of compounds against the Coxsackie virus, B-2 strain (CVB-2), Polio virus type-1 (Polio-1), Sabin strain, and Vesicular Stomatitis Virus (VSV), Vaccinia Virus (VV), Herpes Virus 1 (HSV-1) and Respiratory syncytial virus (RSV), A-2 strain, in infected Vero 76 cells, was determined by plaque reduction assays in Vero 76 cell monolayers. To this end, Vero 76 cells were seeded in 24-well plates at a density of 2´10 5 cells/well and allowed to form confluent monolayers by incubating overnight ingrowth medium at 37°C in a humidified CO 2 (5%) atmosphere. Then, monolayers were infected with 250 mL of proper virus dilutions to give 50-100 PFU/well. Following removal of unadsorbed virus, 500 mL of Dulbecco's modified Eagle's medium supplemented with 1% inactivated FCS and 0.75% methyl cellulose, without or with serial dilutions of test compounds, was added. Cultures were incubated at 37°C for 2 (Sb-1 and VSV), 3 (CVB-2, VV and HSV-1) or 5 days (RSV) and then fixed with PBS containing 50% EtOH and 0.8% crystal violet, washed and air-dried. Plaques were then counted, 50% effective concentration (EC 50 ) was calculated by the linear regression technique.
RESULTS AND DISCUSSION
Commercial substituted phenols were selected as starting precursors for the synthesis of oxadiazoles 5a-h. The substituted phenols were converted into the corresponding phenoxy acids 1a-h, prepared previously in our laboratory, by the reaction with 2-bromoalkanoic acids in aqueous solution of NaOH (14), followed by Fischer esterfication (15) in acidic MeOH to give the esters 2a-h. Compounds 2a-h were used directly for the next step without further purification. Treatment of 2a-h with hydrazine hydrate afforded the corresponding hydrazides 3a-h, which gave the 1,3,4-oxadiazole-2-thione/ thiol derivatives 5a-h on treatment with CS 2 and KOH in MeOH. The structures of 3a-h were comfirmed by the 1 H-, 13 C NMR and mass spectra. The cyclization of 3a-h to 1,3,4--oxadiazole-2-thiones (5a-h) was followed by the 1 H NMR spectra where the three NH protons of hydrazides disappeared on the expense of the appearance of broad singlets in the region d 9.91-11.62 ppm, attributed to NH in 5a, 5b, 5d, 5g and 5h. In the case of compounds 5c, 5e and 5f, the 1 H NMR spectra were characterized by the presence of SH signal at d 1.27 ppm; meanwhile, 13 C NMR spectra exhibited signals at d~178.5 ppm, attributed to the C=S carbons, and then supporting the existence of these compounds in the tautomeric form. The signals in the range of d 161.6-163.2 ppm were attributed to C=N of the 1,3,4-oxadiazole-2-thiones. The mass spectral data were consistent with the structures of the synthesized compounds 5a-h.
The key intermediate 4, which was used for coupling of compounds 5a-h with benzothiazole, was prepared by the reaction of chloroacetyl chloride with 2-aminobenzothiazole (17) . The benzothiazole derivatives 6a-h were obtained by condensation of 4 with compounds 5a-h, using anhydrous K 2 CO 3 in acetone. The structures of 6a-h were confirmed by IR, 1 H-, 13 C NMR and mass spectra. The 1 H NMR spectra exhibited additional signals in the aromatic region, in addition to a singlet for SCH 2 protons of the acetamide part in the region d 4.42-4.63 ppm. The signal for SCH 2 carbon was oriented in the 13 C NMR spectra in the region d 35.9-36.2 ppm. The mass fragmentation patterns were consistent with the suggested structures; however, the FABMAS spectra showed the protonated molecular ions of these compounds.
Cytotoxicity was measured on MT-4 cells. None of the in vitro tested compounds were found to inhibit HIV-replication, at EC 50 lower than the CC 50 , compared to the antiviral agent efavirenz (EFV) (18) . Thus, no selective anti-HIV activity could be witnessed (EC 50 > 100 mg mL -1 ). As compared to the known antiviral agent Cidofovir (19) , no activity was found for any of the compounds at non-toxic concentrations.
Compounds 6d and 6e were found to be the prominent cytotoxic and selective ones toward leukaemia cell lines CCRF-CEM with CC 50 12 ± 2, and 8 ± 1 mg mL -1 , respectively. In comparison with the antitumor agent doxorubicin (20) as a control, all the tested analogues 6a-h were inactive against the other ten cancer cells lines with CC 50 100 mg mL -1 .
The metabolic biotransformation of 6d and 6e in human cells might be mediated through the CYP1 family of cytochrome P450s (21) .
Comparison of the activities of compounds 6a to 6h showed that the inclusion of the two chloro substituents in the 3',4'-positions (compound 6e) shifted the threshold of potency from the inactive side toward activity, particularly against the CD4+ human acute T-lymphoblastic leukaemia cell line (CCRF-CEM) (CC 50 = 8 ± 1 mg mL -1 ). The acti-vity was decreased by structural changes with a single chloro substituent (e.g., in compound 6d CC 50 = 12 ± 2 mg mL -1 ). On the other hand, upon replacement of the chloro substituent of 6d or 6e with a bromo substituent (6b), a slight decrease in leukaemia inhibitory activity (CC 50 = 14 ± 3 mg mL -1 ) was observed.
CONCLUSION
In summary, in vitro screen led to identification of compound 6e (N-(benzothiazol--2-yl)-2-{5-[1-(3,4-dichlorophenoxy)ethyl]-1,3,4-oxadiazole-2-yl-thio}acetamide) as a new antitumor candidate, being the promising agent for further structural modification, and pharmacological evaluation. 
